News & Updates

Women with inflammatory bowel disease (IBD) who use hormonal contraceptives (HCs) appear to be less likely to experience IBD-related symptoms but are more likely to have intestinal inflammation over a year, reports a study.

Subcutaneous methylnaltrexone is safe to use in children with cancer who have opioid-induced constipation, suggest the results of a study. In addition, this agent stimulates bowel movements in more than a third of paediatric patients.

In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achiev­ing steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with un­complicated mild-to-moderately active inflammatory bowel disease (IBD).